Compare CNK & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNK | RCUS |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.6B |
| IPO Year | 2007 | 2018 |
| Metric | CNK | RCUS |
|---|---|---|
| Price | $37.04 | $30.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $33.70 | $31.90 |
| AVG Volume (30 Days) | ★ 2.5M | 1.2M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,115,000,000.00 | $247,000,000.00 |
| Revenue This Year | $11.01 | N/A |
| Revenue Next Year | $3.70 | $45.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $21.60 | $10.07 |
| 52 Week High | $38.98 | $31.74 |
| Indicator | CNK | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 61.01 | 58.95 |
| Support Level | $36.28 | $25.94 |
| Resistance Level | $38.98 | $31.41 |
| Average True Range (ATR) | 0.97 | 1.14 |
| MACD | -0.24 | 0.13 |
| Stochastic Oscillator | 36.10 | 70.80 |
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres. Cinemark manages its business under two reportable segments: U.S. markets and international markets. The majority of its revenue is generated from the U.S. markets segment.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.